Cover Image
Market Research Report

Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019

Published by GlobalData Product code 175085
Published Content info 731 Pages
Delivery time: 1-2 business days
Price
Not Available
Back to Top
Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019
Published: December 13, 2019 Content info: 731 Pages

This publication has been discontinued on January 18, 2020.

Description

GlobalData's clinical trial report, "Triple-Negative Breast Cancer (TNBC) Global Clinical Trials Review, H2, 2019" provides an overview of Triple-Negative Breast Cancer (TNBC) clinical trials scenario. This report provides top line data relating to the clinical trials on Triple-Negative Breast Cancer (TNBC) Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Product Code: GDHC5198CTIDB

Table of Contents

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Triple-Negative Breast Cancer (TNBC) to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Triple-Negative Breast Cancer (TNBC) to Oncology Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 23
  • Clinical Trials in E7 Countries by Trial Status 24
  • Clinical Trials by Phase 26
  • In Progress Trials by Phase 27
  • Clinical Trials by Trial Status 28
  • Clinical Trials by End Point Status 30
  • Subjects Recruited Over a Period of Time 31
  • Clinical Trials by Sponsor Type 33
  • Prominent Sponsors 34
  • Top Companies Participating in Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials 36
  • Prominent Drugs 38
  • Clinical Trial Profile Snapshots 39

Appendix 749

  • Abbreviations 749
  • Definitions 749
  • Research Methodology 750
  • Secondary Research 750
  • About GlobalData 751
  • Contact Us 751
  • Disclaimer 751
  • Source 752

List of Tables

  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials by Region, 2019* 7
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 14
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 15
  • Proportion of Triple-Negative Breast Cancer (TNBC) to Oncology Clinical Trials, G7 Countries (%), 2019* 17
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
  • Proportion of Triple-Negative Breast Cancer (TNBC) to Oncology Clinical Trials, E7 Countries (%), 2019* 22
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials by Phase, 2019* 26
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 35
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 37
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures

  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials by Region (%), 2019* 7
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 8
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 14
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 15
  • Proportion of Triple-Negative Breast Cancer (TNBC) to Oncology Clinical Trials, G7 Countries (%), 2019* 16
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
  • Proportion of Triple-Negative Breast Cancer (TNBC) to Oncology Clinical Trials, E7 Countries (%), 2019* 21
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27
  • Triple-Negative Breast Cancer (TNBC) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36
  • Triple-Negative Breast Cancer (TNBC) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38
  • GlobalData Methodology 750
Back to Top